Navigation Links
Repligen Licenses Rights to Use of HDAC3 Inhibitors for Memory Disorders
Date:1/20/2011

WALTHAM, Mass., Jan. 20, 2011 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.  The patent application is based on work conducted at UCI by Dr. Marcelo A. Wood, which demonstrated that one of Repligen's HDAC3 inhibitors improved both the acquisition and persistence of long-term memory in an animal model.  These data were published in the January 12th issue of The Journal of Neuroscience in a manuscript entitled "HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation" (McQuown, S., et al., J. Neurosci. (2011) 31:764 –774).  Under the terms of the license agreement, UCI will receive an upfront payment, development milestones and royalties upon successful commercialization of an HDAC3 inhibitor for certain memory disorders.  Upon issue, the patent will remain in force until 2031 prior to any regulatory extensions.

"These new data indicate that HDAC3 inhibitors should be further evaluated for use in a variety of disorders in which the acquisition or extinction of a long-term memory is a factor," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We intend to continue to investigate the potential of our selective HDAC3 inhibitors in a variety of disease models."

The manuscript published in The Journal of Neuroscience examined the role of HDAC3 inhibitors in long-term memory using a combined genetic and pharmacologic approach.  In the study, a genetic approach was used to delete HDAC3 in the hi
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
11. Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015  AccuTec Blades, Inc. today announced ... Blades division.  EPC announced in May 2015 its intent ... Verona, Virginia and Obregon, Mexico ... sale process. Rick Gagliano , ... Blades said, "Our new name, AccuTec Blades, reflects the ...
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... DALLAS , Sept. 1, 2015 UT ... and distinguished faculty members joined U.S. Representatives ... in a roundtable discussion on the 21 st ... biomedical research currently being considered by the ... faculty – including National Academy of Sciences members, department ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... Conn., May 15, 2012 /PRNewswire-iReach/ -- Global ... important Cambridge Healthtech Institute conferences: IMVACS – ... August 13 – 15, Cambridge, MA - The ... under one heading: the Seventh Annual Novel Vaccines, Design ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, ... results for the three months ended March 31, 2012 ... delighted with recent developments that have strengthened and advanced ... David Dodd. "Our Phase 1/2 therapeutic vaccine trial continues ...
Cached Medicine Technology:Attendees Save up to $350 on CHI Conferences This Summer by Registering Through Global Information 2GeoVax Labs Reports 2012 First Quarter Financial Results 2GeoVax Labs Reports 2012 First Quarter Financial Results 3GeoVax Labs Reports 2012 First Quarter Financial Results 4GeoVax Labs Reports 2012 First Quarter Financial Results 5GeoVax Labs Reports 2012 First Quarter Financial Results 6
(Date:9/1/2015)... ... ... September is National Prostate Cancer Awareness Month and Florida Hospital Zephyrhills wants to ... the United States. , Prostate cancer is to men what breast cancer is to ... men. One new case occurs every 2.3 minutes and a man dies from prostate ...
(Date:9/1/2015)... ... , ... According to a study published August 25th in the ... a three year study about weight loss and diabetes were far more likely to ... surgery at the onset of the trial. In fact, the participants in the trial ...
(Date:9/1/2015)... ... 2015 , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session ... Compass® has taken place at Kingsborough Community College in Brooklyn in each of the ... for Calvary, and two junior counselors who were campers themselves just a few years ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, TX ... , an innovative vaginal health laser procedure that prevents and resolves dryness in ... atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse and ...
Breaking Medicine News(10 mins):Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... University School of Medicine (BUSM) have discovered new details ... team connected pharmacological properties of the Novartis Pharma AG ... first time after investigating adverse reactions suffered by patients ... osteoporosis. These findings appear online in the Journal ...
... executed a license agreement with The Incubation Factory, St. Louis, ... is pending. The tonometer was developed by a ... Robert Fechtner, MD, director of the glaucoma division at UMDNJ. ... the research team. "We are excited that this ...
... HealthDay Reporter , MONDAY, May 16 (HealthDay News) -- ... "bad" cholesterol levels, and may in fact prompt a very modest ... The finding comes from a six-month examination of the impact ... healthy people in England. , , "The issue is that there ...
... Elsevier, the world-leading publisher of scientific, technical ... launch of Mosby,s Textbook of Dental Nursing. Written ... Assessment Centre for Dental Nurses, Eastman Dental Institute ... of Oral Medicine, Pathology and Microbiology, University of ...
... , WORCESTER, Mass. A new book edited by ... Brook University School of Medicine provides a comprehensive look ... at the leading cause of death---heart disease. "Regenerating the ... is edited by Glenn Gaudette, associate professor of biomedical ...
... institutionalized Romanian children have found that the length of ... correlates with lower IQ and behavioral problems. A ... and Tulane University, shows that early adversity even affects ... as telomeres, and hastening how quickly their cells "age." ...
Cached Medicine News:Health News:NJIT and UMDNJ license personal tonometer technology for innovative glaucoma testing 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 3Health News:New book explores stem cell therapies for heart disease 2Health News:Deprivation and neglect found to age children's chromosomes 2Health News:Deprivation and neglect found to age children's chromosomes 3
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: